Preclinical evaluation of a SARS-CoV-2 variant B.1.351-based candidate DNA vaccine
Description
The SARS-CoV-2 pandemic revealed the critical shortfalls of global vaccine availability for emergent pathogens and the need for exploring additional vaccine platforms with rapid update potential in response to new variants. Thus, it remains essential
